Risk factors for systemic fungal infections in liver transplant recipients
β Scribed by J. Briegel; H. Forst; B. Spill; A. Haas; B. Grabein; M. Haller; E. Kilger; K. W. Jauch; K. Maag; G. Ruckdeschel; K. Peter
- Publisher
- Springer
- Year
- 1995
- Tongue
- English
- Weight
- 962 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0934-9723
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
We sought to determine whether the prophylactic use of amphotericin B products (conventional amphotericin B and liposomal amphotericin B) reduces the incidence of fungal infections in high-risk liver transplant recipients, and if so, whether this lowers the cost of care. The study sample comprised 2
Invasive aspergillosis (IA) is a severe complication of liver transplantation. Risk factors for IA after deceased donor liver transplantation (DDLT) have been presented in several reports, but are not well established for living donor liver transplant recipients. Here, a retrospective case-control s
Prevention of fungal infections following liver transplantation is an important goal, and I appreciate the efforts of Reed et al. 1 to determine the efficacy of prophylactic amphotericin B (AMPH) in high-risk liver transplant recipients. In their study, fungi were isolated from 37 anatomic sites in